Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Galmed Pharmaceuticals Ltd. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 23 | 22 | −1 |
| Shares | 2.81M | 2.52M | −289.4K (−10.3%) |
| Value | $4.47M | $1.70M | −$2.77M (−62.0%) |
New holders (4)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Western Wealth Management, LLC | 59,074 | $38.0K | 0.00% |
| Renaissance Technologies LLC | 31,600 | $21.0K | 0.00% |
| Susquehanna International Group, LLP | 10,103 | $7.00K | 0.00% |
| UBS Group AG | 6,064 | $4.00K | 0.00% |
Sold out (5)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Nantahala Capital Management, LLC | 258,957 | $412.0K |
| P.A.W. Capital Corp | 200,000 | $318.0K |
| BlackRock Inc. | 9,116 | $14.0K |
| JPMorgan Chase & Co | 745 | $1.00K |
| McCarthy Asset Management, Inc. | 700 | $1.00K |